PCOS Healthcare Trends · Evergreen explainer
PCOS and fertility: fewer ovulations, not a closed door
If you have PCOS and you are thinking about pregnancy, the internet tends to offer two extremes: alarm, or a supplement list. The evidence picture is calmer and more specific than either. PCOS, now also called PMOS for polyendocrine metabolic ovarian syndrome, affects fertility mainly because ovulation happens less often or not at all in some cycles, which means fewer chances to conceive across a year. It does not mean pregnancy is out of reach. This piece walks through what the 2023 International Evidence-based Guideline actually says about fertility workup and the order of care, what the largest trials reported in their own numbers, and what a 2026 re-analysis added about insulin resistance, so you can walk into a fertility appointment knowing what a complete conversation usually covers.
The one mechanism that explains most of it
Conception needs an egg to be released. Clinicians call a cycle with no egg released an anovulatory cycle, and call the broader pattern ovulatory dysfunction. It is one of the three features used to diagnose this condition, as our explainer on how PCOS/PMOS is diagnosed sets out, and our glossary defines ovulation and related terms in plain words.
When ovulation is irregular, the arithmetic is simple: fewer ovulatory cycles in a year means fewer chances, so conceiving can take longer even when nothing else is wrong. Top-ranking fertility explainers and the World Health Organization fact sheet they cite describe PCOS as the most common cause of anovulation worldwide. The same sources also make a second point that often gets lost: because the main barrier is ovulation itself, clinicians describe this cause of infertility as among the more treatable kinds. That is the framing the sources use. It is not a promise about any one person, and the sections below keep it that way.
A complete workup looks beyond PCOS
A common early mistake is to treat PCOS as the whole fertility story. The 2023 guideline describes a broader check before any conclusions are drawn:
- Your own history in dates. Cycle length and variation, how long you have been trying, prior pregnancies, and the screening that travels with this condition, including glucose status. Our explainer on insulin resistance in PCOS/PMOS covers why glucose is checked at diagnosis and re-checked over time.
- Partner factors. The guideline frames its fertility recommendations for cases with anovulation alone and a normal semen analysis, which is its way of saying a partner check is part of a complete workup, not an afterthought.
- Other causes. The guideline says the question of checking whether the fallopian tubes are open should be weighed case by case, based on personal history, costs and the complexity of the planned care, before ovulation-focused care with timed intercourse or insemination begins. In plain words: whether that test belongs in your workup is an individual decision, not an automatic step and not an automatic skip.
- Age and timing. How long to try before seeking help, and how urgently to move, depends in part on age and on how long you have already been trying. Those thresholds are a conversation to have explicitly at a first visit, not a number to guess from a chart online.
Preconception health: the guideline list
Before trying to conceive, the guideline asks that a set of general health items be looked at for people with this condition: weight, blood pressure, smoking, alcohol use, diet and activity, sleep, and mental health. It also advises counselling on how weight can affect fertility and pregnancy, while noting that the evidence behind parts of that advice is of low certainty. Two fences belong around this list. First, it is a health review list, not a pass or fail test you must clear before anyone will help you. Second, it applies at any body size: our piece on lean PCOS explains why the same screening floor applies when weight is not part of the picture.
The order of care the guideline describes
The guideline describes care in steps, with lifestyle support alongside each step rather than as a hurdle before it. In its own wording, it names a medicine called letrozole as the first-line pharmacological treatment for ovulation induction in people with this condition who are not ovulating and who have no other infertility factors. It notes that this use is still off-label in many countries. It describes other medicines, procedures and in vitro fertilisation (IVF) as later options in the sequence when earlier steps do not lead to pregnancy or when other factors are present.
This page reports that order because patients deserve to know what guideline their clinician is working from. It does not recommend any step for you, it gives no doses, and it ranks nothing for your case. Which step, if any, fits depends on your full workup, your age, how long you have been trying, and your own priorities, decided with your clinician.
What the largest trial reported
The trial most often cited for the guideline position above is PPCOS II (Pregnancy in Polycystic Ovary Syndrome II), a United States trial that randomly assigned 750 women with PCOS to one of two ovulation medicines for up to five cycles. The researchers reported live births in 27.5 percent of the letrozole group and 19.1 percent of the comparison group, and ovulation in 61.7 percent of letrozole cycles compared with 48.3 percent of comparison cycles. Read those numbers the way researchers intend them: they are group results from one trial population, over a set number of cycles, in people who met that trial entry rules. They describe what happened on average in that study. They do not predict what will happen for you, and a single percentage from a headline is not a personal chance.
What a 2026 re-analysis added: insulin resistance before pregnancy
In 2026, researchers published a secondary analysis of the same PPCOS II trial data in Obstetrics and Gynecology, asking whether insulin resistance measured before pregnancy was linked to outcomes. Among 746 women, they reported that higher pre-pregnancy insulin resistance (grouped by a measure called HOMA-IR) was associated with lower ovulation rates (93.5 percent in the lowest group compared with 73.8 percent in the highest), lower clinical pregnancy and live birth rates, later first ovulation, and a higher recorded rate of gestational diabetes (13.8 percent in the lowest group compared with 45.7 percent in the highest). They also reported that improvement in the insulin resistance measure during treatment was associated with higher odds of clinical pregnancy in that dataset.
The authors conclusion, in their own framing, is that assessing insulin resistance before conception may matter for reproductive success and pregnancy risk. Note what kind of finding this is: a secondary analysis looks back at data collected for an earlier question, so it shows associations in that group, not proof that changing one number will change an outcome for a given person. Its practical use at an appointment is narrow and real: it is one more reason the guideline glucose checks described above belong in a fertility workup conversation.
If pregnancy happens: closer monitoring is part of the guideline picture
The 2023 guideline treats PCOS as a higher-risk status in pregnancy and asks that it be flagged in prenatal care, with monitoring and support to match. The risks it lists as higher include greater pregnancy weight gain, miscarriage, gestational diabetes, high blood pressure conditions including preeclampsia, preterm birth and caesarean delivery. That list is a reason for early booking and planned checks, not a forecast: many pregnancies in people with this condition proceed without those complications, and the guideline point is that the care team should know the history from the start. Our queued companion piece on PCOS and pregnancy will cover that monitoring in more depth.
What this does not mean
- PCOS does not mean infertility. Many people with this condition conceive without any fertility care, including people who were told as teenagers that pregnancy would be difficult. Irregular ovulation lowers the number of chances per year. It is not the same as no chance.
- A high AMH result is not a fertility verdict. AMH reflects a pattern in the ovaries and has a defined role in adult diagnosis under the 2023 guideline. It does not, on its own, tell you whether or when you will conceive.
- Regular cycles do not rule out an ovulation question, and irregular cycles do not prove one. Cycle pattern is a clue your clinician weighs with the rest of the workup, which is why dated records help. Our guide to questions to bring to a first appointment shows how to prepare that record.
- No food, supplement or programme in this piece is a fertility treatment. This page makes no claim that anything improves your chance of conceiving. If a product is marketed to you with that promise, the question to ask is which trial, in which population, measured live birth, and what the guideline says about it.
Questions to bring to a fertility visit
- Based on my cycle record, do we have evidence that I am ovulating, and how was that assessed?
- Is my glucose status up to date, and should insulin resistance be part of my preconception picture? Who owns the re-check date?
- Has a partner check been done, and are there any other factors we should rule in or out before we attribute timing to PCOS alone?
- Does tubal checking belong in my workup, now or later, and what drives that decision in my case?
- Given my age and how long we have been trying, what timeline are we working to, and when would we change the plan?
- What does the guideline sequence look like in my case, step by step, and what would make us move from one step to the next?
- If I become pregnant, what extra monitoring do you plan, and who coordinates it? Our piece on which clinician does what maps how an obstetrician, an endocrinologist and a reproductive endocrinologist divide that work.
What this means when you are finding care
Fertility care for this condition usually sits with a reproductive endocrinologist, often alongside your obstetrician-gynaecologist and, for the metabolic side, an endocrinologist or your primary clinician. The clinician you want can show you the whole workup, not just the PCOS part, and can state the timeline and the next-step triggers in plain words. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state, for example the Florida listings page, and skim the plain-language glossary before a visit.
Sources
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology and Metabolism, 2023, including its fertility and pregnancy sections (preconception review, tubal patency as an individual decision, and the first-line ovulation induction statement) — read the guideline (PMC)
- Prepregnancy Insulin Resistance and Fertility and Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome, Obstetrics and Gynecology, 2026, secondary analysis of PPCOS II (PMID 42166772) — read the study abstract (PubMed)
- The guideline programme home at Monash University — Monash Centre for Health Research and Implementation, PCOS
- Federal overview of the condition — NICHD, PCOS topic page
- Top-ranking explainer used as the bar for this piece — AppsHealthy, PCOS Fertility: Ovulation, Letrozole and IVF Options
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.